Literature DB >> 31014963

Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions.

Sonali Kochhar1, Ed Clarke2, Alane Izu3, Kebonethebe Emmanuel Kekane-Mochwari3, Clare L Cutland4.   

Abstract

BACKGROUND: A globally standardized approach in high and low and middle-income countries (LMIC) to actively monitor the safety of vaccines for pregnant women during development and implementation phases is critical. Brighton Collaboration's (BC) Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project has developed globally standardized case definitions (CDs) of key obstetric and neonatal terms for the assessment of safety of vaccines in pregnancy. CDs are categorized into levels of diagnostic certainty, facilitating their use in varied settings. This study evaluates the field performance of CDs in LMIC.
METHODS: Data from pregnant participants of RCTs for trivalent inactivated influenza vaccine conducted at Chris Hani Baragwanath Academic Hospital, South Africa (SA) between 2011 and 2013 were reviewed retrospectively for preterm birth, stillbirth and hypertension CDs and the Gestational age assessment (GA) algorithm. Data from an ongoing pneumococcal vaccine trial (conducted at MRC Unit, The Gambia) were collected prospectively for GA.
RESULTS: For GA, 600 mother-infant dyads from Gambia and 155 mother-infant dyads from SA were reviewed. Level 2B (unsure LMP and US in 2nd trimester) was the most common level seen in Gambia (63%) and level 3B1 (unsure LMP with physical examination) in SA (43%). Preterm deliveries had similar results in SA. The pregnancy-induced hypertension definition performed well, with 96% (54/56) of cases fulfilling 'level 1' for 'preeclampsia with severe features'. 24 stillbirths were identified and 21 records were reviewed; 73.3% (11/15) of the stillbirths classified as antepartum by attending physicians and 83.3% (5/6) of the intrapartum stillbirths did not fulfil the criteria for any level of certainty.
CONCLUSION: BC CDs for neonatal and maternal outcomes (preterm and hypertension) and GA were sensitive, reliable and feasible to use in RCTs in SA and Gambia. Modifications to the stillbirth CD are required to improve its usefulness in varied settings.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  AEFI; Adverse events following immunisation; Brighton Collaboration; Case definitions, evaluation; Clinical trials; Diagnostic certainty; GAIA; Gestational age; Hypertension; IMPRINT; Immunisation; LMIC; Low resource setting; Maternal immunisation; Pregnancy outcomes; Pregnant women; Preterm birth; Safety; Stillbirth; Ultrasound; Vaccines

Mesh:

Year:  2019        PMID: 31014963     DOI: 10.1016/j.vaccine.2019.03.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Risk Measurement of Perinatal and Neonatal Morbidity Characteristics and Applicability of GAIA Case Definitions: Results and Lessons Learnt of a Hospital-Based Prospective Cohort Study in the Valencia Region (2019-2020).

Authors:  Antonio Carmona; María Latorre Tejerina; Alicia Martínez Sebastián; Dafina Dobreva; Cristina P Jurca; Sergio Huerta Barberá; Vicente Bernat Montoya; Mercedes Aristoy Zabaleta; Ana Pineda Caplliure; Beatriz Mansilla Roig; María Navío Anaya; Ricardo Tosca-Segura; Miguel Tortajada-Girbés; Javier Díez-Domingo; Alejandro Orrico-Sánchez
Journal:  Int J Environ Res Public Health       Date:  2022-06-10       Impact factor: 4.614

2.  Maternal and neonatal data collection systems in low- and middle-income countries: scoping review protocol.

Authors:  Mabel Berrueta; Ariel Bardach; Agustin Ciaponni; Xu Xiong; Andy Stergachis; Sabra Zaraa; Pierre Buekens
Journal:  Gates Open Res       Date:  2020-02-05

3.  Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.

Authors:  Gerald Voss; Jeanne-Marie Jacquet; Nadia Tornieporth; Beate Kampmann; Ruth Karron; Ajoke Sobanjo-Ter Meulen; Robert Chen; Marion Gruber; Nicole Lurie; Charlie Weller; Jakob P Cramer; Melanie Saville; Mimi Darko
Journal:  Vaccine       Date:  2021-11-17       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.